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Lynch syndrome (LS) is characterised by predisposition to colorectal, endometrial 
and other cancers and is caused by inherited pathogenic variants affecting the DNA 
mismatch repair (MMR) genes MLH1, MSH2, MSH6 and PMS2.  It is probably the 
most common predisposition to cancer, having an estimated prevalence of between 
1/100 and 1/180.  Resources such as the International Society for Gastrointestinal 
Hereditary Cancer’s MMR gene variant database, the Prospective Lynch Syndrome 
Database (PLSD) and the Colon Cancer Family Register (CCFR), as well as 
pathological and immunological studies are enabling advances in the understanding 
of LS.  These include defined criteria by which to interpret gene variants, the function 
of DNA mismatch repair in the normal control of apoptosis, definition of the risks of 
the various cancers, and the mechanisms and pathways by which the colorectal and 
endometrial tumours develop, including the critical role of the immune system.  
Colorectal cancers in LS can develop along three pathways, including flat 
intramucosal lesions, which depend on the underlying affected MMR gene.  This 
gives insights into the limitations of colonoscopic surveillance and highlights the 
need for other forms of anti-cancer prophylaxis in LS.  Finally, it shows that the 
processes of autoimmunisation and immunoediting fundamentally constrain the 
development of tumours in LS and explains the efficacy of immune checkpoint 
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Lynch syndrome (LS), previously called hereditary non-polyposis colorectal cancer 
(HNPCC), is probably the most common major cause of inherited susceptibility to 
cancer, with an estimated prevalence in the general population of between 1/100 and 
1/180.[1]  It is characterized by predisposition to a range of cancers, involving most 
frequently the colorectum and endometrium, and also many other organ sites including 
ovary, stomach, small intestine, hepato-biliary tract, pancreas, urinary tract, prostate, 
brain and sebaceous skin tumours.[2, 3]   
LS is caused by constitutional (germline) pathogenic variants affecting one of four 
genes encoding the DNA Mismatch Repair (MMR) system components: MLH1, MSH2, 
MSH6, and PMS2, and hence the current commonly accepted diagnostic definition of 
LS is carrying such a variant.[1, 4-8]  However, while we acknowledge there is an 
opinion that LS can only be diagnosed in such individuals once cancer has been 
diagnosed, this is contrary to the hereditary polyposes, which are characterised by the 
macroscopic syndromic feature of multiple pre-malignant tumours.[9]  Allied to this, a 
major purpose of diagnosis of a cancer predisposing condition is to identify those who 
would benefit from surveillance and prophylactic surgery to prevent cancer.[5]  Hence, 
our view is that it is inconsistent and to a degree cruel to discriminate against LS by 
expecting such individuals to develop cancer in order to be diagnosed with the 
condition, especially as cancer does not always occur.[2, 3, 10]  As we discuss later 
on, the definition of LS could, and perhaps should, therefore, move to one that 
incorporates recently identified specific microscopic and molecular pre-malignant 
syndromic features.   
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DNA MMR recognises and repairs mismatched bases (e.g. C opposite T) and 
insertions or deletions in repetitive sequences.  In LS patients, this MMR gene 
constitutional variant, when combined with an acquired second pathogenic variant due 
to somatic mutation in the wild-type allele of the same MMR gene, results in the 
complete loss of MMR pathway function in the affected cells.  Deficiency of MMR 
(dMMR) leads to hypermutability, resulting in an increase in the mutation rate by 100- 
to 1000-fold due to uncorrected base mismatches, and to microsatellite instability 
(MSI) due to variation in the lengths of repetitive sequences (e.g. AAAAAAA… or 
CACACACA…. or similar, known as microsatellites) due to uncorrected 
insertion/deletion loops that are prone to occur as DNA replication errors in repetitive 
sequences.[11]  However, crucially, dMMR does not simply fail to repair mismatches, 
it elicits a reduced susceptibility to apoptosis induced by DNA damage recognised by 
the MMR pathway.[11-14]   
The International Society for Gastrointestinal Hereditary Cancer (InSiGHT) was the 
first expert group to define pathogenicity of gene variants according to an agreed set 
of criteria based upon Bayesian probability, using the 5-tier classification system of 
Plon et al.[4, 15-17]  In this system Class 5 variants are pathogenic and Class 4 likely 
pathogenic, with Class 3 being variants of uncertain significance (VUS), and Classes 
2 and 1 being likely benign and benign respectively.  InSiGHT maintains the world 
reference database of variants observed in MMR genes (as Leiden Open Variation 
Databases (LOVD), which are now linked to ClinVar, as part of the ClinVar-ClinGen 
partnership), and accordingly, 82% of the Class 4 and 5 variants listed affect MLH1 
and MSH2, with 13% affecting MSH6 and 5% PMS2.[16, 18-20]  It should be noted 
that these pathogenic variants are mostly from cases ascertained by family history.  
As more cases of LS are ascertained from systematic testing of cancer cases and 
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incidentally from gene panel testing, more patients will be identified with pathogenic 
variants in MSH6 and PMS2 and thus the proportions due to the different MMR genes 
will alter.[6] 
All types of variants are seen as pathogenic: nonsense, frameshift, splice site, 
missense, insertion-deletion and large deletions/rearrangements, the largest so far 
being a 10 Mb inversion affecting MSH2 and which is visible cytogenetically.[21-23]  
Approximately 60% of all putative pathogenic missense mutations causing LS actually 
disrupt splicing and are thus, in effect, truncating.[24]  Up to 3% of Lynch syndrome 
cases are due to variants involving the 3′ end of the EPCAM gene (immediately 
adjacent to MSH2), that results in the hypermethylation of the MSH2 promoter or 
partial deletion of MSH2.[25, 26]  Another infrequent, but important cause of LS is 
constitutional methylation of the MLH1 promoter, which occurs in 1 – 2% of cases.[27-
29]  This is usually sporadic in nature, so neither inherited nor heritable, and relatives 
are therefore not at risk.  However, in a small number of patients the hypermethylation 
is secondary to a large deletion typically involving LRRFIP2, the gene upstream of 
MLH1, and it is the deletion which is the pathogenic variant: the methylation is 
secondary.[29]  Given the risks to relatives it is therefore important to distinguish such 
cases, and this is achieved by testing both the tumour and constitutional DNA, and 
finding MLH1 promoter methylation in both, perhaps in the context of a LS family 
history.  It has to be borne in mind that approximately 15% of sporadic colon cancers 
are also dMMR due to somatic, so acquired, epimutation of both MLH1 alleles by 
promoter hypermethylation.[30]  This is a function of such tumours arising from right-
sided serrated lesions.[31].  A similar proportion of sporadic endometrial cancers also 
have biallelic hypermethylation of MLH1, and as with colon cancers a small proportion 
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are due to constitutional methylation plus a somatic mutation in the normal MLH1 
allele.[27, 28, 32, 33] 
 
Other genetic conditions relating to Lynch syndrome 
Muir-Torre syndrome (MTS) is a descriptive diagnosis of an individual in which both 
skin sebaceous neoplasms (and keratoacanthoma-like lesions) and a “visceral” 
carcinoma of any sort has occurred.[34, 35]  It is a frequently seen combination in LS, 
indeed on close inspection many, perhaps most patients with LS who have suffered a 
carcinoma probably have a sebaceous skin lesion and thus MTS.[36, 37]  However, 
MTS is also seen in other heritable predispositions, e.g. MUTYH-associated 
adenomatous polyposis, or it may be sporadic, so while a marker of possible LS, MTS 
is not diagnostic.[38, 39]  Notably, although sebaceous lesions and hyperplasia are 
often rightly a cause for concern regarding LS and a patient with sebaceous lesions 
and a visceral cancer warrants testing, it should be noted that in the absence of a 
family or personal history of LS-associated cancer they are at low risk and do not 
warrant testing.[40, 41]   
Individuals may inherit pathogenic variants in both copies of a DNA MMR gene.  When 
both are in the same gene it causes Constitutional Mismatch Repair Deficiency 
(CMMR-D) syndrome.  CMMR-D is a classic recessive DNA repair disorder typically 
characterised by childhood onset leukaemia, lymphoma, colorectal and brain cancers, 
but also, in contrast to LS, some patients may have multiple colorectal adenomas.[42-
44]  Signs suggestive of neurofibromatosis type 1 also often occur, such as café-au-
lait macules and cutaneous neurofibromata, plus other features such as immune 
deficiency.[45]  In CMMR-D patients abnormal MMR IHC is seen in both normal and 
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tumour cells (hence the necessity always to test all four markers) and it is possible to 
detect constitutional MSI in e.g. blood.[46, 47]  Patients with CMMR-D due to MSH6 
or PMS2 variants may show milder disease and later onset.[48]  Comprehensive 
diagnostic criteria and care pathways have been published.[7, 45]   
Patients may also be found who have pathogenic variants in more than one MMR 
gene, so-called digenic LS.  It is not clear if this is more severe than LS due to a 
pathogenic variant in one gene, but has clear implications for clinical genetic 
counselling.  However, LS patients can and do co-inherit other forms of predisposition 
to cancer (or indeed any other genetic condition), and if this is suspected should be 
pursued.[49]   
Finally, Turcot syndrome, a combination of colorectal cancer or adenomas and central 
nervous system tumours, with dominant or recessive inheritance, is another historical 
descriptive diagnosis that has been related to LS.  However, it is now known that it 
can be due to CMMR-D, Familial Adenomatous Polyposis and probably other 
conditions, and so as an ambiguous term it should be abandoned.[42, 44, 50] 
 
2. DNA Mismatch Repair Mechanisms 
The MMR pathway is a highly evolutionarily-conserved mechanism responsible for the 
correction of base mismatches (e.g. C or G opposite T or A) and insertion/deletion 
loops (occurring in repetitive sequences such as AAAAAA … or CACACACA … due 
to insertion or deletion of an extra repeat unit during stalled DNA replication of these 
repetitive sequences).  Such stalling is probably mostly due to replication associated 
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errors, but is also caused by DNA damage due to oxidative stress, lipid peroxidation, 
base deamination, methylation, and alkylation.[51] 
A base mismatch or single nucleotide insertion/deletion error is recognized by the 
MutSα complex which is composed of MSH2 and MSH6 proteins.  Insertion/deletion 
loops of 2-8 nucleotides are recognized by the alternative complex MutSβ, composed 
of MSH2 and MSH3 proteins.  MutSα complex activation is characterized by ATPase 
activity, which is important for the interaction with the mismatched DNA and initiation 
of repair.  The binding of MutSα stimulates ATP-hydrolysis leading to a conformational 
change which subsequently triggers the recruitment of a second complex MutLα, 
composed of MLH1 and PMS2 proteins.  The tetrameric complex, by sliding on the 
DNA, searches for the single-strand DNA mismatch on the new strand (daughter 
strand).  This, in turn, activates proliferating cell nuclear antigen (PCNA) and 
Replication factor C (RFC). MutLα possesses an intrinsic ATP-stimulated 
endonuclease activity that requires activation by PCNA in order to create an incision 
in the recently synthesised daughter strand (containing the error).  The incision step 
is followed by the recruitment of exonuclease 1 (EXO1) that removes the newly-
synthesized DNA strand up to and beyond the mismatch or loop. DNA polymerase δ 
re-synthesizes the DNA, whilst Ligase 1 seals the remaining nick.[52] 
The MMR pathway is involved in a signalling cascade that leads to cell cycle arrest 
and / or apoptosis, if DNA damage has previously occurred.[53]  It has been observed 
that MMR-deficient cells fail to recruit ataxia-telangiectasia mutated (ATM) and ATM 
and Rad3-related (ATR); and this prevents p53 phosphorylation in response to DNA 
damage.[12, 54]  The underlying mechanisms by which MMR proteins promote DNA 
damage-induced cell cycle arrest and apoptosis have not been fully elucidated.  Two 
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models have been hypothesised: the futile cycling model and the direct damage 
signalling model.  In the futile cycling model, MMR recognizes the mismatches 
triggering the excision of the newly synthesized strand, although the persistent 
offending damage on the template strand cannot be excised. MMR initiates futile repair 
cycles, eventually resulting in the formation of DNA double-strand breaks and thus, 
activating the ATM/ATR/p53 signalling pathway to activate cell cycle arrest and / or 
apoptosis.[55]  In the direct damage signalling model, MutSα and MutLα directly recruit 
ATM/ATR and cause cell cycle arrest and / or apoptosis.[56] 
A crucial consequence of this is that the low background level of DNA damage in 
normal cells may stimulate MMR and thus inhibit the cell cycle, or if severe even 
stimulate apoptosis, and so net cell turnover does not reach its theoretical maximum.  
However, if MMR deficiency should occur in such cells there is then no such limitation 
by stalling of the cell cycle or activation of apoptosis and net cell division increases in 
an uncontrollable fashion, allied to which as a secondary phenomenon the mutation 
rate increases, which is manifest as MSI and/or abnormal MMR IHC.  This is very 
useful diagnostically, but it is important to appreciate that it is not the increased 
mutation rate per se that is driving the carcinogenic process, and neither does it make 
adenomas progress any quicker than usual.[14]  However, because mutations are 
strongly biased towards repetitive DNA sequences in dMMR cells this has profound 
consequences for the biology of such tumours and patients with LS due to the strong 
immunological responses this elicits.[57, 58]  The critical consequences of this are 
manifest in how LS tumours develop and potentially evade the immune system.[59] 
Notably, some MMR gene variants are associated with abnormal MMR IHC in 
tumours, but not MSI, and vice versa.[4, 15]  In addition, only one of 149 PMS2 
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pathogenic variants causative of LS is a missense mutation.[18]  However, many other 
PMS2 missense variants are seen in CMMR-D (a recessive DNA repair disorder), 
which is consistent with common, but not complete, overlap between loss of DNA 
(MMR-recognised) damage repair and apoptotic functions of MMR.[18, 60, 61] 
 
3. Lynch Syndrome Databases 
In addition to the MMR gene variant database maintained by InSiGHT, there are other 
phenotypic databases aimed at understanding the precise risks LS patients face.  
Initial risk estimates were liable to ascertainment bias and thus tended to overestimate 
by being necessarily retrospective.  The penetrance and expressivity of MMR 
pathogenic variants differs in LS patients according to the MMR gene, age, sex, and 
environmental / lifestyle factors.[62]  Several lifestyle factors, such as smoking, 
alcohol, obesity, are associated with an increased risk of sporadic cancer and have 
been suggested to have similar effects in LS patients.  Therefore, as it is fundamental 
to quantify accurately the risks of developing cancer for LS patients, then in order to 
provide adequate data for surveillance and care, as well as understand the underlying 
biology, the Prospective Lynch Syndrome Database (PLSD) was established in 2012 
by the Mallorca Group of InSiGHT.[2, 63]  The PLSD collects data on LS patients from 
Lynch Syndrome expert centres and registries worldwide, who are thus undergoing 
colonoscopic surveillance with polypectomy, and may also be having therapeutic or 
prophylactic surgery.  It therefore provides information on the natural history of the 
disease course and the effects of interventions and lifestyle factors.  The PLSD is 
linked to the InSiGHT MMR LOVD: all patients on the PLSD must have a Class 4 or 5 
MMR variant, so pathogenic or likely pathogenic according to the InSiGHT 
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classification.[4, 15]  The PLSD includes basic information on pathogenic genetic 
variants, sex, and age, plus information such as cancers or pre-cancers diagnosed, 
age at diagnoses, age at prophylactic surgical removal of organs and information on 
pre-cancers.  Every patient is followed as an individual, as the family history is ignored 
so as not to introduce bias, and the database now has >50,000 patient-years of 
observations.[10]  The PLSD website is public and allows anyone to determine the 
risks to an individual of an LS-associated cancer in an interactive graphical form 
according to their affected gene, age, gender and whether previously affected by 
cancer.[63]  Risks of LS-associated cancers to age 75 are summarised in Table 1; 
those for PMS2 affecting both sexes are combined due to the smaller numbers 
available and numbers have been rounded throughout for clarity.[10] 
Table 1. 
Important parallel efforts have been made in defining risks in Lynch syndrome by the 
Colon Cancer Family Registry (CCFR) and the International Mismatch Repair 
Consortium (IMRC).[64, 65]  The CCFR is an international consortium of six institutes 
in the United States, Canada and Australasia formed as a resource to support studies 
on the aetiology, prevention, and clinical management of colorectal cancer, and 
utilises a form of modified segregation analysis to minimise retrospective 
ascertainment bias.[65, 66]  It currently has data on >42,500 individuals from over 
15,000 families on its records and has made significant advances in demonstrating 
how environmental and lifestyle factors affect cancer risks in LS, such as smoking, 
raised body mass index and alcohol consumption.[67-69]  By contrast, reduced cancer 
risk is seen with, e.g. hormone replacement therapy, vitamin and mineral supplements, 
NSAID use, and parity, but there is no change in risk associated with oral contraceptive 
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use.[70, 71]  The IMRC is a worldwide collaboration of more than 115 investigators 
from 59 centres, with 20,000 individuals with LS from 8,800 families, facilitated by 
InSiGHT and the Collaborative Group of the Americas on Inherited Gastrointestinal 
Cancer (CGA-IGC).[64, 72] 
Lastly, is the initiative to determine the effects of aspirin prophylaxis on LS patients, 
although this is a series of clinical trials rather than a database.  Remarkably, the 
CAPP2 trial has shown that only two-four years of treatment with 600 mg/d of aspirin 
very significantly reduces the risk of colorectal cancer up to more than 10 years post 
treatment, and likely also reduces the risks of other LS cancers, although this is less 
certain.  Notably, side-effects possibly attributable to aspirin were at a low rate and 
actually slightly more common, though non-significantly, in the placebo compared to 
treatment arm.[73-75]  A follow on randomised double blind dose non-inferiority trial, 
CaPP3, is now in progress to determine the optimum dose of aspirin for long term 
prophylaxis.[76] 
 
4. Pathology of Lynch Syndrome Cancers 
Typical histological features of Lynch Syndrome tumours are best exemplified by 
colorectal cancer (CRC), which often shows a combination of the presence of 
prominent tumour-infiltrating lymphocytes, Crohn-like peritumoural lymphoid 
aggregates, poor differentiation, frequently with areas of mucinous and / or signet-ring 
cell patterns, sometimes with a medullary growth pattern.[77, 78]  These 
characteristics can be seen in both Lynch Syndrome CRC and sporadic dMMR bowel 
cancers, but are not sufficiently specific to distinguish them from pMMR cancers. 
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Less data have been published about non-colorectal LS-associated cancers.  LS-
associated endometrial cancers can be seen more frequently in the lower uterine 
segment than sporadic cancers, are mostly of endometrioid type, often with poor 
differentiation, solid or dyscohesive, with prominent tumour-infiltrating lymphocytes, 
and Crohn-like peritumoural lymphoid aggregates.[79-84]  LS-associated ovarian 
cancers are typically of endometrioid or clear cell type, with some tumour-infiltrating 
lymphocytes.[79, 80, 85, 86]  LS-associated gastric carcinomas are mostly of 
intestinal-type with fewer of diffuse-type, and rarely of mucinous type, and an 
associated immune gastritis is reported.[87-90]  LS-associated small intestinal 
adenocarcinomas often display mucinous, signet-ring cell or medullary differentiation, 
with tumour-infiltrating lymphocytes and Crohn-like reactions, as do ampullary 
adenocarcinomas.[91]  LS-associated pancreatic cancers are mostly acinar cell 
carcinomas and medullary carcinomas.[92] 
 
5. Testing for Lynch Syndrome Cancers 
Testing of (usually selected) patients with CRC, EC and/or other types of LS-
associated cancer is recommended by many guidelines and organizations, generally 
starting with testing the tumours for either the presence of MSI or the absence (or 
abnormal expression) of mismatch repair proteins.  There is no consensus regarding 
whether MMR immunohistochemistry or MSI testing is the better first test in colorectal 
cancers as they have similar test performance characteristics in detecting LS: 
sensitivity of MSI is 88 ~ 100% and IHC 73 ~ 100%, with specificity of MSI 68 ~ 84% 
vs IHC 78 ~ 98%.[93, 94]  They may be used serially, or in combination.[93-97]  
However, evidence is now emerging that IHC may be the preferred option when testing 
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endometrial cancers (systematic testing of which is now under consideration by NICE) 
as a recent UK study has shown that while MSI and IHC have similar specificity (83.7 
vs. 81%), MSI has only 56.3% sensitivity compared to 100% for IHC.[82, 83] 
MMR immunohistochemistry is the better option for small biopsies, cancers with a low 
tumour cell proportion or intense inflammatory reaction.  Subsequent testing for MLH1 
promoter hypermethylation and somatic (rather than constitutional / germline) 
mutations can be used to clarify the risk of inherited pathogenic variants in suspected 
Lynch Syndrome patients.  MLH1 promoter hypermethylation testing may be used as 
an alternative to BRAF V600E mutation analysis in colonic cancers.[98-100]  The use 
of larger targeted gene mutation panels (or whole exome / genome sequencing) that 
includes MMR tumour testing with mutation analyses is becoming more 
widespread.[101]  
Immunohistochemical staining for the four major DNA mismatch repair proteins 
(MLH1, MSH2, MSH6 and PMS2) is probably the most common test used to screen 
CRCs and other tumours for dMMR.[93, 95, 97]  The nuclear expression of all four 
proteins suggests mismatch repair proficiency with microsatellite stability.[102-104]  
Loss or abnormality of nuclear staining for any of the proteins indicates dMMR and 
suggests the most likely MMR gene involved.[103, 104]  Loss of MSH2 alone or loss 
of both MSH2 and MSH6 suggests a mutation or abnormality in MSH2 is most likely.  
Similarly, loss of MLH1 alone or loss of both MLH1 and PMS2 suggests an underlying 
mutation, abnormality or promoter methylation in MLH1.  Combined loss of both MSH2 
and MSH6 (or of both MLH1 and PMS2) reflects the heterodimeric binding of MSH2 
with MSH6 (or of MLH1 with PMS2) in the mismatch repair complex MutSα (or of 
MutLα), such that loss of the first protein partner generates instability and loss of the 
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second [37].  Usually, there is nuclear staining in the nuclei of both tumour cells and 
adjacent normal epithelial cells, stromal cells and lymphocytes.  
In a dMMR tumour due to MSH2 mutation there is loss of nuclear expression of MSH2 
and MSH6 and intact staining for MLH1 and PMS2.  In a dMMR tumour due to MLH1 
mutation there is loss of nuclear expression of MLH1 and PMS2 and intact staining for 
MSH2 and MSH6.  This pattern of combined MLH1 and PMS2 loss could be seen 
either in a sporadic tumour (most commonly due to MLH1 promoter methylation) or in 
LS due to constitutional MLH1 mutation.  Correct MMR IHC interpretation requires 
adequate internal control staining of the adjacent stromal and lymphoid cells to confirm 
good fixation of the tissue region.[102, 103]  Patchy intact nuclear staining may occur 
due to variable fixation, or tissue hypoxia, or unequal antibody diffusion.[105, 106]  
Cytoplasmic staining may occur, but if nuclear staining is lost this is considered 
abnormal indicating dMMR.[107]  Weak, patchy, nucleolar staining, or sometimes 
absence of MSH6 expression has been described in rectal tumours following 
neoadjuvant treatment without MSI or a mutation confirmed by molecular testing.[108, 
109]  Notably, heterogeneous staining or loss of MSH6 expression can be due to a 
secondary (non-germline) acquired somatic mutation in the MSH6 coding 
mononucleotide tract.[110, 111]  Approximately 3–10% of LS-associated dMMR 
tumours show no abnormality on immunohistochemical testing (presumably because 
of variants that disrupt normal MMR protein function, but nonetheless enable protein 
detection by IHC).[112] 
Testing DNA extracted from tumours for microsatellite instability (MSI), involves 
investigating for the presence of extra alleles (longer or shorter) at a microsatellite 
locus compared with normal microsatellite length (as determined from normal tissue 
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or blood) from the same individual.[113]  Microsatellites vary in their propensity to 
show instability, and thus the frequency with which the same microsatellite is altered 
varies in different tumour types.  Instability is more likely to be observed at 
mononucleotide repeats (e.g. AAAAA …), than at dinucleotide repeats (e.g. 
CACACA …).  Microsatellite loci or markers used in colonic cancer MSI testing are 
known to have reduced sensitivity at detecting MSI in non-colonic cancers, including 
endometrial, small intestinal, or gastric cancers, in tumours from LS patients with 
MSH6 or PMS2 mutations and in colonic adenomas.[114]  Therefore, a proportion of 
LS-associated tumours may not appear to have MSI using the standard MSI test (but 
might be identified by abnormal MMR immunohistochemistry). 
The efficacy of MMR IHC and MSI may be significantly enhanced by testing more than 
one tumour from the same individual or family, particularly if there are tumours that 
are multiple or rarely seen in LS (e.g. colorectal adenomas, small intestinal cancers, 
hepato-biliary, upper urinary tract and cutaneous sebaceous tumours).[15, 115]  
Consistent immunohistochemical abnormality of one mismatch repair protein in more 
than one tumour from an individual or family represents very good evidence for variant 
pathogenicity.[15, 116]  Some CRCs due to MUTYH-associated polyposis (MAP) or 
proof-reading polymerase-associated polyposis (PPAP) may exhibit MSI and/or 
abnormal immunohistochemistry due to somatically acquired MMR gene mutations. 
Approximately 13-15% of sporadic colonic cancers have dMMR, usually due to 
epigenetic silencing of both alleles of MLH1 by promoter hypermethylation.  Hence, 
while overall unselected dMMR colonic cancers have a relatively poor positive 
predictive value for LS, as the proportion of colonic cancers with MSI due to LS varies 
with age then this can be exploited clinically.  Under the age of 57 y, more than half of 
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all dMMR colonic cancers will be due to LS, whereas over this age less than half will 
be, although even at age 70 approximately 25% dMMR colonic cancers will be due to 
LS (Figure 1).[8, 104, 117]  In contrast, pMMR has a good negative predictive value 
for LS.  Further tests (BRAF mutation and MLH1 methylation tests) are required for 
MLH1-negative cancers to distinguish between LS and sporadic origin.[93, 94, 96]  
Another important practice point is that rectal cancers are distinct from colonic cancers 
in the diagnosis of LS.  Because sporadic colonic cancers with dMMR largely arise 
from right-sided serrated lesions, sporadic rectal cancers with dMMR are 
correspondingly rare, if they occur at all, and hence a rectal cancer with dMMR at any 
age must be considered to be due to LS until proven otherwise.[118, 119]  
(Figure 1) 
The activating missense variant BRAF p.V600E occurs in sporadic colonic cancers 
with dMMR, but not in those due to LS; therefore, BRAF p.V600E is highly predictive 
of the tumour being of sporadic origin rather than LS.[31, 93, 94, 96, 120]  However, 
sporadic tumours may occasionally occur in patients with LS, so the absence of BRAF 
p.V600E does not definitively diagnose LS, but it does indicate that LS is more likely.  
Alternatively, detection of MLH1 gene promoter hypermethylation in a colonic cancer 
provides good, although not unequivocal, evidence that the tumour is sporadic in 
origin, as occasional sporadic tumours do occur in LS and constitutional MLH1 
promoter methylation can be found in a small proportion of patients with LS.[28, 29]  
BRAF p.V600E testing is only of use in distinguishing colorectal cancers; it has no 
utility in e.g. endometrial cancer. 
LS is definitively diagnosed following tumour testing by constitutional/germline MMR 
gene sequencing to identify a pathogenic constitutional variant.[4-6, 121]  Patients with 
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digenic LS, who have inherited pathogenic variants in more than one MMR gene, are 
occasionally seen (and more will be as gene panel testing becomes prevalent), but it 
is unclear if their risks are increased over those patients with a pathogenic variant in 
one MMR gene.  It is often useful to have samples from more than one individual in 
the family, because case segregation studies may be required in order to determine 
pathogenicity or whether an individual is a phenocopy.[4, 15]  If the family shows 
evidence of hereditary transmission of LS, but no point mutation is found, then tests 
for large-scale mutations, such as deletion of a whole exon (or more), can be 
performed; some 12 – 40% of pathogenic variants are of this type.[21, 23, 122-127]  
LS-related tumour types that are rare in the general population, and thus have a high 
predictive value for LS, such as small intestinal and hepatobiliary cancer, upper urinary 
tract and bladder (under age 60y) transitional cell carcinoma, or skin sebaceous 
adenoma/carcinomas are therefore worth testing.[40]  Synchronous or metachronous 
bowel cancers are also significant, as is the development of any two LS-related 
tumours (e.g. CRC and endometrial cancer), and all such cases warrant testing for 
LS. 
 
6. Neoplastic Precursors in Lynch Syndrome 
When LS was being defined in the early 1990s the only known pathway to CRC was 
based on the work of Dukes, Bussey and Morson on Familial Adenomatous Polyposis: 
firstly Dukes’ concept of “simple tumours and cancer” in 1925 as part of his system for 
the staging of rectal cancer in FAP, followed by the adenoma to carcinoma pathway 
in 1958.[128-130]  Naturally, the reasonable assumption was made that the same 
pathway applied in LS and thus colonoscopic surveillance to remove premalignant 
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adenomas would be beneficial in LS.  When early data started to come in on the 
efficacy of surveillance in LS it became obvious that there was a large number of 
interval cancers, and moreover these occurred despite the interval between 
colonoscopies being steadily reduced to less than three years and sometimes even 
less than one year, because it appeared that LS cancers developed much more rapidly 
than sporadic ones, assuming they all arose from adenomas.[6, 131]  Moreover, 
because of the increased mutation rate, the MSI, observed in LS cancers allied to the 
prevailing concept that genomic instability characterised all cancer, it was further 
assumed that this must be what was driving a faster adenoma-carcinoma progression, 
although not all parties were convinced.[11, 14, 132]  In addition, although dMMR 
adenomas could be found in LS patients, further doubts were raised when aspirin 
treatment failed to reduce the incidence of adenomas (although it later reduced that of 
CRCs), and results from the PLSD became available.[2, 73, 116, 133, 134]  LS 
patients on colonoscopic surveillance at various intervals could finally be 
compared.[133]  Remarkably, within the limits measurable, colonoscopy did not 
appear to reduce the rate at which colorectal cancers were arising in LS patients, 
despite it being associated with a significant reduction in mortality and, in addition, 
stage was not related to the interval since last colonoscopy – completely the opposite 
of population screening programmes which are based primarily on adenoma 
removal.[2, 133-135]  What was going on?  Although LS patient survival is certainly 
improved by colonoscopic surveillance enabling earlier diagnosis and a degree of 
downstaging, together this mass of evidence was leading to the conclusion that a 
pathway independent of adenomas must be occurring and moreover a pathway in 
which precursors were less obvious on colonoscopy.[94]   
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At about the same time, it was discovered that LS patients harbour an enormous 
number of dMMR crypts in the colorectum (~1/cm2 mucosa, so ~10,000 
crypts/patient), which are not dysplastic, and yet LS patients only go on to eventually 
develop between zero and perhaps one, two or three cancers.[136, 137]  Could these 
be leading to cancers, perhaps by an occult route?  This was answered shortly 
afterwards by the finding of flat intra-mucosal cancers in which the wnt pathway was 
activated by mutations not in APC, as in classical adenomas, but in beta-catenin, 
indeed mutations in repetitive coding sequences, exactly as predicted would result 
from dMMR.[138]  Intriguingly, subsequent work to sequence LS cancers has shown 
that some 61% of APC mutations are predicted to occur after MMR deficiency occurs, 
as they are found in repetitive sequences, exactly as would be expected in dMMR 
tumours.  Hence, a proportion of these beta-catenin-mutant flat lesions acquire 
secondary APC mutations, thence to become polypoid adenomas and subsequently 
cancers.[139, 140]  Thus, it is now understood that there are at least three pathways 
to colorectal cancers in LS, not including the occasional sporadic colonic cancer due 
to a right-sided sessile lesion, which are occasionally observed (Figure 2).  The first 
pathway is via sporadic adenomas which acquire secondary dMMR.  The second 
pathway is via flat cancers within the mucosa that arise directly from dMMR crypts, 
and the third pathway is LS-specific adenomas that arise from these flat lesions due 
to secondary APC mutations.[139]  Hence, a proportion of LS colorectal cancers arise 
from flat lesions which are inherently more difficult to detect, let alone remove, on 
colonoscopy, explaining at least in part the apparent high rate of interval cancers, but 
also removing the need to invoke a faster progression rate in LS.  Building on this, it 
has been shown that the cancers in patients with LS due to PMS2 mutations arise 
largely along pathway 1, from sporadic adenomas, going further to explain why 
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patients with pathogenic PMS2 variants have only a small increased risk of CRC.[141]  
Intriguingly, very recently it has been found that pathway 2 predominates over pathway 
3 in patients with pathogenic MLH1 variants, but pathway 3 predominates over 
pathway 2 in those with MSH2 pathogenic variants.[142].  These fascinating findings 
have clear implications for future surveillance strategies, which of necessity must now 
also include modalities such as aspirin prophylaxis and vaccines to address the 
inherently limited efficacy of colonoscopy and increased risks of cancers in LS at sites 
other than the large bowel, which are becoming the predominant cause of mortality in 
LS patients under surveillance.[2, 3] 
(Figure 2) 
It is of note that a number of observers have now found dMMR glands in 
morphologically normal endometrium from LS patients, which in turn has implications 
for the understanding of LS carcinogenesis in that organ.[143] 
 
7. Immune Escape of Lynch Syndrome Neoplasms 
The early general observations of large local tumours and a lower rate of metastasis, 
together with a strong immune reaction to LS cancers, such as increased tumour 
infiltrating lymphocytes (TIL) and tertiary lymphoid structures (TLS; also termed Crohn-
like peritumoural lymphoid aggregates or follicles), later backed up by gene expression 
signatures characteristic of immune cell activation, all indicate an important role for the 
immune system in LS.[57, 144, 145]  However, this needs to be put in the context of 
the normal immune architecture in the bowel.  Gut-associated lymphoid tissue (GALT) 
comprises both isolated and aggregated lymphoid follicles in both the small and large 
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intestines.  Humans have approximately 30,000 isolated lymphoid follicles (ILF), 
scattered throughout the large and small intestine, but especially in the colon.[146]  
ILFs vary in their distribution within the large and small intestines, may be mucosal or 
sub-mucosal, and at their simplest may consist of a single follicle, with or without some 
T-cells.[147, 148]  They are considered to be the main source of immune priming in 
the colon and from where Crohn’s disease originates, and they have specialised 
follicle-associated epithelium (FAE), which overlies a subepithelial dome containing 
numerous macrophages, dendritic cells, T, B lymphocytes, and special antigen 
sampling microfold/M/cells.[149, 150]  The FAE has a crucial role in the initiation of 
the mucosal and systemic immune responses.[151]  However, the relationship 
between Crohn-like follicles in LS and ILF in normal colon is not completely clear.  In 
LS, the follicles are generally peritumoural and not located inside cancers, and, 
although they do not have FAE, they do have T cells, B cells and germinal centres.[58, 
152]  Whether they are induced de novo, as in chronic inflammation or develop from 
submucosal ILFs remains to be determined.[153]  Crohn-like follicles/TLS are found 
in CRCs apart from LS, however, the frequency/number is highest in LS patients 
compared to sporadic dMMR and pMMR CRCs which is not simply related to age.[58] 
In recent years, there has been a growing interest in TLSs in a variety of cancers 
including CRC, in particular as prognostic indicators of cancer progression and 
responses to immunotherapy.[150, 154]  In hepatocellular carcinoma, intratumoral 
TLSs correlated with a lower risk of early relapse after surgery.[155]  In sarcoma, 
melanoma and renal cell carcinoma, both intratumoural location and the presence of 
B cells (but not T cells) and particularly germinal centres correlate with improved 
outcomes to checkpoint blockade immunotherapy.[156-158]  Further studies of the 
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location, cellular composition and presence of germinal centres in TLS in hereditary 
dMMR may therefore shed light on their role in Lynch Syndrome. 
In dMMR cells predictable mutations can and do occur in repetitive protein coding 
sequences and result in frameshift peptides (FSP).[159-161]  Such FSPs are novel 
antigens and elicit both humoral and cellular immune responses, which are seen as 
TILs around the dMMR crypts in LS patients as well as in dMMR cancers, both 
sporadic and due to LS.[136, 160, 162, 163]  In the face of such responses how is it 
possible for tumours, let alone cancers, to develop in LS?  The answer lies in the 3-
step process of elimination, equilibrium and escape.[59, 164]  Cells generating FSPs, 
presented on their surface by MHC-I are subjected to attack by cytotoxic T-
lymphocytes (CTL), resulting in elimination.  However, such cells that randomly 
manage to acquire activating mutations in PD-L1 before they are eliminated can hold 
the immune system to a local standstill (activating the PD-1 – PD-L1 immune 
checkpoint) – the process of equilibrium.  Subsequently, if before being eliminated 
these cells manage to acquire inactivating mutations in MHC-I or MHC-II (HLA Classes 
I & II) that abrogate presentation of FSPs on their surface they are then able to escape 
the immune system, at least locally.  Given the huge number of dMMR crypts in an LS 
patient, but that the average LS patient manifests between zero and one, two or three 
CRCs, it is clear that the process of elimination must be highly efficient, giving a 
different perspective on cancer biology.[2, 139] 
A number of different escape mechanisms have been observed.  The commonest, 
seen in approximately 30% of dMMR CRCs, is mutation of beta-2-microglobulin (B2M) 
which prevents MHC-I presentation of FSPs.  This was an early observation, the full 
significance of which is only now apparent.[165-169]  The outgrowth of such B2M 
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mutant clones is a prime example of cancer immunoediting, which has been further 
related to variation in host immune function, e.g. mucosal density of FOXP3-positive 
T-cells, indicating that such factors may be additional modifiers of LS.[170]  
Importantly, B2M mutations in dMMR cancers are significantly associated with an 
almost zero rate of metastasis, and thus indicate highly favourable prognosis.[171, 
172]  In addition to mutations in B2M, mutations of CIITA or RFX5 are seen in 
approximately 20% of dMMR CRCs, and prevent MHC-II antigen presentation, while 
approximately 10% of dMMR CRCs have mutations of TAP1 or TAP2, which are 
antigenic peptide transporters responsible for antigen presentation, thus also 
preventing antigen presentation on the cell surface.[173, 174]  In such ways tumour 
cells escape the attentions of the host’s immune system, both locally and in the 
circulation, but are in turn liable to attack with help from immunotherapy, such as anti-
PD-1 or PD-L1 immune checkpoint blockade.[175, 176] 
The full variety of mechanisms by which tumours, and dMMR tumours in particular, 
manage to evade the immune system has yet to be determined.  Undoubtedly, the 
colorectal microbiome plays an important part in the process of CRC development in 
LS as well as sporadically.[177]  Intriguingly, the immune response to dMMR CRCs in 
the form of development of high endothelial venules (HEV) responsible for trafficking 
lymphocytes into lymphoid follicles/TLS is stronger in LS patients, than in sporadic 
dMMR colonic cancers, and especially high HEV densities in B2M-mutant tumours 
support the concept of immunoediting during tumour evolution.[58]  Such higher HEV 
densities in B2M-mutant tumours imply that under strong immunoselective pressure 
created by immune cells recruited via HEVs, tumour cells which have lost MHC class 
I antigens gain growth advantage due to immunoediting, thus revealing a major role 
of HEVs in enhancing the immunoselective pressure on highly immunogenic cancers.  
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Taken together with the high numbers of dMMR crypts in LS and the low numbers of 
CRCs that actualy manifest, these findings all point toward a longer process of 
immunoediting in Lynch syndrome CRCs, possibly due to the pre-existing dMMR 
crypts immunising LS patients against their own propensity to cancer, and explaining 
the higher proportion of B2M mutations in LS compared to sporadic CRCs.[58, 136, 
137]  However, these HEV generally recruit naïve lymphocytes from the blood in to 
tissues and HEV-containing Crohn-like aggregates are generally seen in a 
peritumoural location in both pMMR and dMMR cancers, so our understanding of HEV 
and TLS in LS is as yet incomplete.[58, 152, 178] 
 
8. Conclusions 
The major carcinogenic effect of dMMR is to reduce apoptosis and increase the net 
cell turnover rate.  The raised mutation rate per se is of little or no consequence, but 
the bias to frameshift mutations in repetitive sequences caused by dMMR is of 
considerable fundamental consequence, firstly in auto-immunising LS patients to 
FSPs and secondly in thus modifying the evolution of dMMR cancers by 
immunoediting. 
That some MMR gene variants are associated with abnormal MMR IHC in tumours, 
but not MSI, and vice versa, plus the observation of, for example, certain PMS2 
variants in cases of CMMR-D , but not LS, challenges the concept of in vitro functional 
tests in assessing variant pathogenicity.[4, 15, 18, 60, 61]  Which function should be 
tested: DNA repair, or apoptosis, or both?[4, 179-181]  We would therefore advise 
caution in the interpretation of such assays until this is clarified. 
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It is now understood that there are three main pathways to CRC in LS, including via 
sporadic adenomas, but also via occult intramucosal dMMR crypts and then Beta-
Catenin-mutant flat cancers which are directly invasive, some of which acquire 
secondary APC mutations to become polypoid.[138, 139]  Moreover, the likelihood 
that tumours follow particular pathways is related to the underlying gene affected by a 
pathogenic variant, and hence the variation in expression of LS starts to be explained 
and may lead to surveillance protocols becoming more tailored to genotype.[3, 10, 
141, 142] 
Currently, LS is defined by an individual carrying a pathogenic variant in an MMR gene, 
but of necessity to interpret variants as pathogenic often requires tests on tumours for 
dMMR.[4, 6]  As part of the interpretational process tests of MMR function may be 
performed in vitro, but this too is problematic and so interpretation cannot be based 
solely on such analyses.[4, 179-181]  However, the recent advances in understanding 
the pathways and responses to cancer in LS brings forward the possibility of 
alternative means to diagnose LS independent of cancer itself, indeed perhaps even 
an alternative definition involving the immune system.  The nature of the intense 
immune response to cancers in LS, manifest as the stronger HEV response seen in 
individuals with LS from an early age (16y), allied to specific T and B-cell responses 
to FSPs can be considered syndromic features characteristic of LS.[58, 160, 163]  In 
addition, the dMMR crypts seen in the normal large bowel mucosa, and the dMMR 
glands seen in normal endometrium can also be considered syndromic features 
characteristic of LS.[136]  So, all taken together we may be approaching a definition 
of LS in molecular terms, one in which the development of cancer, while of great 
importance clinically, is not necessary to achieve diagnosis.  This in turn may enable 
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the classification as pathogenic of many variants in MMR genes, and MSH6 and PMS2 
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Average Risks of Lynch syndrome-associated Cancers to age 75y  
Data from the Prospective Lynch Syndrome Database (PLSD).[10, 63]  Note that the 
individuals studied are under colonoscopic surveillance, and may have had 
prophylactic or therapeutic surgery, which is allowed for in the estimates. 
Males 
Cancer type MLH1 MSH2 MSH6 PMS2 
Any cancer 
71% 
[63 - 81%] 
75% 
[66 - 86%] 
42% 




[49 – 68%] 
51% 
[41 – 65%] 
18% 
[8 – 43%] 
See below 
Stomach, small bowel, 
bile duct, gallbladder 
and pancreas 
22% 
[16 – 30%] 
20% 
[14 – 28%] 
8% 
[3 – 30%] 
See below 
Ureter and kidney 
5% 
[3 – 10%] 
18% 
[13 – 25%] 
2% 




[4 – 13%] 
13% 
[8 – 21%] 
8% 






[9 – 22%] 
24% 
[17 – 33%] 
9% 
[3 – 31%] 
5% 
[<1 – 68%] 
Brain 
0.7% 
[<1 – 5%] 
8% 
[4 – 15%] 
2% 




Cancer type MLH1 MSH2 MSH6 PMS2 
Any cancer 
81% 
[74 – 88%] 
84% 
[77 – 91%] 
62% 




[41 – 57%] 
47% 
[39 – 55%] 
20% 




[30 – 47%] 
49% 
[40 – 61%] 
41% 
[29 – 62%] 
3% 
[5 – 50%] 
Ovaries 
11% 
[7 – 20%] 
17% 
[12 – 31%] 
11% 
[4 – 39%] 
3% 
[<1 – 43%] 
Stomach, small bowel, 
bile duct, gallbladder 
and pancreas 
11% 
[7 – 17%] 
13% 
[9 – 19%] 
4% 




Ureter and kidney 
4% 
[2 – 8%] 
19% 
[14 – 27%] 
6% 




[3 – 11%] 
8% 
[5 – 14%] 
1% 




[<1 – 5%] 
3% 
[1 – 8%] 
1% 
[<1 – 23%] 
See below 
 
Both Sexes combined  
Cancer type PMS2 
Any cancer 
34% 
[19 – 60%] 
Colorectal (bowel) 
10% 
[3 – 41%] 
Stomach, small bowel, bile duct, gallbladder and pancreas 
4% 
[1 – 34%] 
Ureter and kidney 
4% 





[0 – 31%] 
Brain 
<1% 
[0 – 31%] 
 
Figure Legends  
Figure 1: Probability by Age that a Colonic Cancer with dMMR is due to Lynch 
Syndrome 
This graph shows the probability by age that a colonic cancer with dMMR is due to 
Lynch syndrome.[8, 104, 117]  Note that this does not apply to rectal cancers, because 
right-sided serrated lesions that give rise to sporadic dMMR colonic cancers do not 
occur in the rectum, and hence a rectal cancer with dMMR is due to Lynch syndrome 
until proven otherwise.[118, 119] 
 
Figure 2: Pathways to Colorectal Cancer in Lynch Syndrome 
There are three pathways to dMMR colorectal cancers in Lynch syndrome.[138, 139]  
Pathway 1: Classic sporadic adenomas, initiated by WNT pathway activation due to 
mutations in APC (APCm), acquire dMMR through somatic mutation of the remaining 
normal MMR allele (MLH1m, MSH2m, MSH6m or PMS2m).  This can occur at any stage 
of the adenoma, from early through to adenoma-carcinoma transition.  Pathway 3: 
crypts which have acquired dMMR due to somatic mutation of the normal MMR allele 
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are not dysplastic, but if they undergo somatic mutation of Beta-Catenin (CTNNB1m) 
which activates the WNT pathway they become flat carcinomas which later acquire 
mutations in TP53 (TP53m), an otherwise rare event in dMMR CRCs.[138, 182]  
Pathway 2: a proportion of Pathway 3 lesions acquire secondary APC mutations and 
thus become polypoid adenomas.  Because of this unique combination of somatic 
events these Pathway 2 adenomas are, as far as is known, specific to LS (hence 
“Lynch-specific dMMR Adenomas”).  Regarding Pathways 2 & 3 in their original 
proposal, Ahadova and colleagues remark: “For better visibility, pre-malignant lesions 
that do not develop into cancer are not included in the diagram, because their number 
greatly exceeds the number of carcinomas.”[139]  Pathway 1 predominates in patients 
with LS due to PMS2 pathogenic variants, while CTNNB1-mutant tumours are more 
likely in MLH1 patients and APC-mutant tumours are more likely in MSH2 and MSH6 
patients.[141, 142]  Note that sporadic colonic cancers that arise from serrated lesions 
with MLH1 deficiency due to somatic biallelic hypermethylation of the MLH1 promoter 
can and do occur in LS, albeit perhaps less often due to the enhanced immunity in LS 
patients against dMMR cells, because of chronic autoimmunisation from the novel 
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